• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/10

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

10 Cards in this Set

  • Front
  • Back

Enbrel (etanercept)


Clearance

Receptor-mediated processes

-->increased plasma levels upon repeated dosing


Hepatobiliary and renal


-->predicted metabolic processes



Rituxan (rituximab)


Clearance

Receptor mediated processes including Ab-mediated cytotoxic (ADCC) pathways


Hepatobiliary and renal elimination of catabolized Ab molecules (predicted)

Lantis (insulin glargine)


Clearance

Renal and hepatic

Avonex (interferon beta-1a)


Clearance

Renal elimination (predicted)

Omalizumab (Xolair)


Receptor

binds to circulating IgE in plasma to form an inactive complex as part of its MOA

Bevacizumab (Avastin)


Receptor

binds to circulating VEGF in the plasma to form an inactive complex as part of its MOA

Muromanab (OKT3)


Immunogenicity

For allograft rejection


25%

Abciximab (Reopro)


Immunogenicity

for angioplasty


6-44%

Rituximab (Rituxan)


Immunogenicity

For Non-Hodgkin lymphoma


11%

Infliximab (Remicade)


Neutralizing Ab

Chimeric IgG1k MAb


¼ pts develop HACA


-->decrease t ½ from 190 to 48hrs